Related Experiment Videos
Determination of doxorubicin and doxorubicin-3-ol in rat heart
Abstract:
The discovery of a delayed form of DXR-induced cardiotoxicity raises the question whether the presence of the drug or of metabolites in myocardial cells is necessary for the development of cardiotoxicity. The present investigations deal with a new method for the determination of DXR and of its main metabolite, DXR-3-ol, in cardiac cells. Rat hearts "ex-vivo", isolated 24 h after i.v. administration of 6 mg/kg DXR and 20 micro C of DXR-14C, were perfused with ice-cold Tyrode solution, which releases anthracyclines from extracellular spaces. After homogenization DXR and DXR-3-ol were extracted from the cell at room temperature. The separation was carried out by HPLC; the recovery was about 95%, measured by the extracted radioactivity compared with that of the pellet residue.
Insights
Researchers developed a new method to detect Doxorubicin (DXR) and its metabolite DXR-3-ol in cardiac cells. This helps understand if the drug or its metabolites are essential for DXR-induced cardiotoxicity.
Area of Science:
- Pharmacology
- Cardiology
- Analytical Chemistry
Background:
- Doxorubicin (DXR) can cause delayed cardiotoxicity.
- The necessity of intracellular drug or metabolite presence for cardiotoxicity is unknown.
Purpose of the Study:
- To develop and validate a new method for quantifying DXR and its primary metabolite, DXR-3-ol, within cardiac cells.
- To investigate the intracellular presence of DXR and DXR-3-ol in relation to cardiotoxicity.
Main Methods:
- An "ex-vivo" rat heart model was utilized 24 hours post-DXR administration.
- Hearts were perfused to remove extracellular anthracyclines.
- Intracellular DXR and DXR-3-ol were extracted after homogenization.
- High-Performance Liquid Chromatography (HPLC) was employed for separation and quantification.
Main Results:
- A novel method for determining DXR and DXR-3-ol in cardiac cells was established.
- Extraction and HPLC separation provided reliable quantification.
- High recovery rates (approximately 95%) were achieved, validated by radioactivity measurements.
Conclusions:
- The developed method allows for the accurate measurement of intracellular DXR and DXR-3-ol.
- This technique is crucial for further research into the mechanisms of DXR-induced cardiotoxicity.
- Understanding intracellular drug levels can inform strategies to mitigate cardiac side effects.